TELO

Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1

Retrieved on: 
星期四, 五月 30, 2024
Human, Zeus, Safety, Ageing, Animal, Research, CMO, Arthropathy, Pet, TELO, Entrepreneurship, Vaccine

TAMPA, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps as a potential treatment for age-related conditions, today announced the commencement of several significant milestones. These events underscore its commitment to advancing innovative treatments to mitigate the effects of aging and the continuation of its groundbreaking work.

Key Points: 
  • These events underscore its commitment to advancing innovative treatments to mitigate the effects of aging and the continuation of its groundbreaking work.
  • These studies are potentially usable for veterinary as well as human IND purposes.
  • Telomir-1 is the Company’s therapeutic candidate aimed at addressing age-related diseases in humans and animals.
  • In parallel with the pivotal canine study, the Company also announced that it is currently using Telomir-1 to treat Zeus, a 12-year-old German Shepherd.

New to The Street TV Announces Episode 575 with its Four Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV, Saturday, May 25, 2024, at 6:30 PM ET

Retrieved on: 
星期五, 五月 24, 2024
Online, Sequence, Initial public offering, Chromosome, Tax, Host, Street, Interview, Entrepreneurship, FDA, Golf, Nobel Prize, Phase 1, Ageing, MD, Medication, Growth, IPO, Culture, Larosa, Bloomberg Television, TELO, Family

New to The Street airs episode 575 on Bloomberg TV as a sponsored programming Saturday, May 25, 2024, at 6:30 PM ET, featuring the following four (4) corporate interviews:

Key Points: 
  • New to The Street airs episode 575 on Bloomberg TV as a sponsored programming Saturday, May 25, 2024, at 6:30 PM ET, featuring the following four (4) corporate interviews:
    1).
  • Pharmaceutical - Telomir Pharmaceuticals, Inc.'s (NASDAQ: TELO) ($TELO) ("Company") interview with Chris Chapman, MD, Co-founder, Chairman, Chief Executive Officer, and Chief Medical Officer.
  • Telomir is a pharmaceutical company in the pre-clinical stage focused on groundbreaking studies in aging.
  • Dr. Chapman explains that the scientific community has yet to further advancements in the reduction or growth of telomeres after cell divisions.

Telomir Pharmaceuticals, Inc. Signs Media Deal with New to The Street for Network Interview Broadcasts, Billboards, and TV Commercial Support

Retrieved on: 
星期四, 五月 16, 2024
Copper, Iron, DNA, Television, FDA, Digital, Osteoarthritis, Health, Ageing, Research, Cancer, Social media, Metal, Notifiable disease, Inflammation, Fox Business, Bloomberg Television, TELO, Zinc

New to The Street's TV anchors will interview Telomir Pharmaceuticals Inc.'s management team, introducing and discussing the Company's development of its novel TELOMIR-1 drug , designed to affect age reversal.

Key Points: 
  • New to The Street's TV anchors will interview Telomir Pharmaceuticals Inc.'s management team, introducing and discussing the Company's development of its novel TELOMIR-1 drug , designed to affect age reversal.
  • Each filmed segment will air as sponsored programming on Bloomberg TV and the FOX Business Network .
  • The New to The Street's social media team and television network partners will re-share media content, creating a platform to increase awareness about TELO.
  • New to The Street's TV interviews with Telomir Pharmaceuticals, Inc.'s (NASDAQ: TELO) management, airings as sponsored programming on Bloomberg TV and the Fox Business Network , "To Be Announced."

Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.

Retrieved on: 
星期二, 四月 16, 2024
Osteoarthritis, Economics, TELO, Hematology, Animal, Cleveland Clinic, Research, IND, Weakness, DRS, Medicine, Press club, Ageing, Longevity, Pharmaceutical industry

WASHINGTON, April 16, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on Telomir-1 as a potential treatment for age-related conditions, today recapped its presentation of compelling pre-clinical data on Telomir-1 at a high-profile event hosted at the National Press Club in Washington, D.C., on April 15, 2024.

Key Points: 
  • As part of its commitment to transparency and openness in sharing its research data, during the event, Drs.
  • Chapman and Roizen presented company data that showed the effect of Telomir-1, a novel molecule designed to modulate telomerase activity and elongate telomeres.
  • The data show that telomeres lengthened in vitro in human cells and telomerase activity increased by 40%.
  • “Our National Press Club event was our first opportunity to share on a national stage Telomir-1’s potential to combat the diseases of aging,” stated Dr. Chapman.

Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024

Retrieved on: 
星期二, 四月 2, 2024
Press club, B cell, Longevity, TELO, Chromosome, Research, DNA, MD, Skin, Osteoarthritis, Blood, Ageing, Pharmaceutical industry

BALTIMORE, April 02, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially address age-related conditions, today announced that anti-aging expert and New York Times bestselling author Michael F. Roizen, MD, will present promising pre-clinical research on Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024. Dr. Roizen serves as Telomir’s special advisor on age reversal.

Key Points: 
  • Dr. Roizen serves as Telomir’s special advisor on age reversal.
  • The search for treatments to combat the diseases of aging has increasingly become the focus of many medical professionals and, more recently, society in general.
  • “Our event at the National Press Club will provide us with an opportunity to share Telomir-1’s potential with the public on a national stage,” stated Chris Chapman, MD, co-founder, chairman, chief executive officer and president of Telomir Pharmaceuticals.
  • As Telomir continues to uncover new and promising data through our pre-clinical work, we remain committed to sharing our data publicly.

Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Retrieved on: 
星期五, 三月 29, 2024
Diagnosis, B cell, Regeneration, TELO, Disease, Research, Nonsteroidal anti-inflammatory drug, MD, Quality of life, Human, Osteoarthritis, FDA, Ageing

BALTIMORE, March 26, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially address age-related conditions, today announced that Telomir and global animal health research company Argenta have agreed to begin a three to six-months study on the efficacy of Telomir-1 as a treatment for osteoarthritis and other diseases of aging in canines.

Key Points: 
  • The study will evaluate the efficacy of Telomir-1 for mitigating the progression of osteoarthritis based on symptomatic, radiographic, gross pathologic and histopathologic evaluations.
  • In addition, Telomir believes that this study could be used as part of its pre-clinicial program for eventually evaluating Telomir-1 in humans.
  • It is estimated that nearly 18 million canines in the United States are affected by osteoarthritis.
  • “Osteoarthritis is the most common ailment in canines yet there are currently no treatments that combat the disease.

Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th

Retrieved on: 
星期五, 三月 22, 2024
B cell, Conference, Longevity, National University Health System, TELO, The New York Times, BGCT, Health, Chromosome, Research, DNA, EDT, Laboratory, MD, Skin, Poster, Telomere, Osteoarthritis, Blood, NUHS, Ageing, Pharmaceutical industry

BALTIMORE, March 22, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially address age-related conditions, today announced that Telomir and Danielle R. Baker, Ph.D., of Frontage Laboratories will present a scientific poster presentation at the Global Longevity Federation Conference in Las Vegas on March 26th at 2 pm EDT. The poster will present new data regarding the effect of Telomir-1 on telomere length in three human cell lines.

Key Points: 
  • The poster will present new data regarding the effect of Telomir-1 on telomere length in three human cell lines.
  • This presentation builds on the data that was presented at the National University Health System of Singapore (NUHS) Centre for Healthy Longevity Conference 2024 in February.
  • “Presenting our poster at the Global Longevity Federation conference offers a significant opportunity for our team to showcase the potential for Telomir-1.
  • To be added to the Telomir Pharmaceuticals email distribution list, please email [email protected] with TELO in the subject line.

Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate’s Potential in DNA Age Reversal Science

Retrieved on: 
星期四, 三月 14, 2024
Toxicity, Notifiable disease, TELO, Entrepreneurship, Science, Research, DNA, Ageing, MD, Quality of life, Drug development, Osteoarthritis, Pharmaceutical industry

Telomir’s recent AI-powered research presented in Singapore last month not only supports but amplifies the therapeutic potential of Telomir-1.

Key Points: 
  • Telomir’s recent AI-powered research presented in Singapore last month not only supports but amplifies the therapeutic potential of Telomir-1.
  • Additional AI-driven studies now being conducted to demonstrate Telomir-1's promising therapeutic potential, supporting Telomir’s hypothesis with solid computational evidence.
  • As part of its work, Telomir works with third-party collaborators Frontage Laboratories and InSilicoTrials, each of whom utilize AI in-silico testing models.
  • To be added to the Telomir Pharmaceuticals email distribution list, please email [email protected] with TELO in the subject line.

Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference

Retrieved on: 
星期四, 三月 7, 2024
Regeneration, AI, MD, Stem cell, Ageing, Drug development, National University Health System, Telomere, CHL, HUVEC, Conference, Longevity, B cell, NUHS, MSC, Poster, TELO, Research, Pharmaceutical industry

The data presented was garnered from pre-clinical studies that Telomir previously disclosed it was undertaking.

Key Points: 
  • The data presented was garnered from pre-clinical studies that Telomir previously disclosed it was undertaking.
  • The data presented further demonstrated how Telomir-1 increases telomere length and its potential to successfully affect age-related inflammatory conditions.
  • The collaboration is expected to help accelerate the development of Telomir-1, improve its safety profile, and significantly reduce the research and development costs of Telomir’s drug development program.
  • To be added to the Telomir Pharmaceuticals email distribution list, please email [email protected] with TELO in the subject line.

Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal

Retrieved on: 
星期二, 三月 5, 2024
Stem cell, Advisory board, Cleveland Clinic, Regeneration, Food and Drug Administration, Blood, Zinc, MD, FDA, Ageing, Food, Cancer, Overload, Life, B cell, Attention, Chromosome, Joint, Metal, Heart, Longevity, Imagination, Science, TELO, Brain, Pharmaceutical industry

BALTIMORE, March 05, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to affect age reversal, today announced that Michael F. Roizen, MD, a leader in age-related medicine and an existing advisor to the Company, will be increasing his role in the coming months as a Special Advisor on Age Reversal.

Key Points: 
  • A board-certified internist and anesthesiologist, Dr. Roizen has been instrumental in the development of many successful ventures.
  • He also served 16 years on Food and Drug Administration (FDA) advisory committee and chaired one for two years.
  • Chris Chapman, MD, co-founder, chairman, chief executive officer and president of Telomir, stated, “Telomir's groundbreaking work has captured the attention and imagination of the industry.
  • We look forward to his continued contributions to our efforts.”
    To be included in the Telomir Pharmaceuticals email distribution list, please email [email protected] with TELO in the subject line.